最新医学 別冊 免疫1 関節リウマチ

出版社: 最新医学社
発行日: 2002-12-25
分野: 臨床医学:一般  >  雑誌
雑誌名:
特集: 関節リウマチ
電子書籍版: 2002-12-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

商品紹介

「関節リウマチ」の患者数は我が国では50万人を超えています。しかし、その病因は未だ解明されていません。現時点では関節リウマチの予防が不可能であることから、早期診断・早期治療が鉄則です。しかし、早期診断は必ずしも容易ではなく、また、治療についても決定的な方法もなく、問題が山積しています。いかに患者の生活の質(QOL)を上げるような治療が可能か、本書は「関節リウマチ」の概念から診断・治療法、治療薬などについて、臨床の場ですぐに役立つ最新情報をお届けします。

目次

  • 表紙
  • 監修
  • 目次
  • 執筆者
  • 第1章 関節リウマチの概念・定義
  • 概念・定義
  • 疫学
  • 第2章 関節リウマチの病理・病態生理
  • 病理―滑膜の炎症から骨破壊まで―
  • 病態生理―サイトカインの面から―
  • 病因
  • 第3章 関節リウマチの関節外病変肺
  • 腎臓
  • アミロイドーシス
  • 第4章 関節リウマチの類縁疾患
  • 悪性関節リウマチ
  • 若年性特発性関節炎
  • 成人Still病
  • 第5章 関節リウマチの診断
  • 診断
  • 検査
  • 画像所見
  • 鑑別診断
  • 活動性の評価と薬効判定
  • 第6章 関節リウマチの管理・治療
  • 薬物療法・選択基準
  • 治療薬剤:
  • (1) 非ステロイド性抗炎症薬 (NSAIDs)
  • (2) 抗リウマチ薬 (DMARDs)
  • (3) ステロイド剤
  • (4) 生物製剤
  • 理学療法
  • 外科療法
  • 経過と予後
  • 医療経済―リウマチ疾患将来予測―
  • 第7章 関節リウマチ治療ガイドライン
  • 関節リウマチ治療ガイドライン
  • 座談会 関節リウマチの治療の現状と展望
  • 略語集
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 関節リウマチの概念・定義

P.15 掲載の参考文献
1) Rothschild B M, et al:Symmetrical erosive peripheral polyarthritis in the late archaic period of Alabama. Science 24:1498-1502, 1988.
2) Winchester R J:The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 56:389-466, 1994.
3) Gregersen P K, et al The shared epitope hypothesis an approach to understanding the molecular genetics of susceptibdity to rheumatoid arthritis. Arthritis Rheum 30:1205-1213, 1987.
4) 斉藤輝信, 他:日本リウマチ財団教育研修会テキスト4版. p319-330. 1999.
5) Weinblatt M E, et al:Methotrexate in rheumatoid arthritis. A five-year prospective multicenter trial. Athritis Rheum 3:1492-1498, 1994.
6) Lopez-Mendez A, et al:Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic disease program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 36:1364-1369, 1993.
7) Gutierrez-Urena S, et al:Pancytopenia secondariy to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272-276, 1996.
8) Kremer J M, et al:Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37:316, 1994.
9) Kirwan J R, et al:The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333:142-146, 1995.
10) Maini R N, et al:Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomized phase III trial. ATTRACT Study Group. Lancet 354:1932-1939, 1999.
11) Weinblatt M E, et al:Atrial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259, 1999.
P.20 掲載の参考文献
1) Silman A J, et al Epidemiology of the rheumatic diseases. Oxford University Press, OXford, 1993.
2) Felson D T, et al Epidemiology of the rheumatic diseases. Arthritis and Allied Conditions, 13th Ed. (Koopman W J, ed), p3. Williams & Wilkins, Baltimore, 1996.
3) Arnett F C, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1998.
4) 居村茂明:疫学と患者実態. 厚生省長期慢性疾患総合研究事業平成9年度研究報告書, p107, 1998.
5) 古田純典:慢性関節リウマチの有病率と発症要因に関する疫学的研究. 平成10年度厚生科学研究費補助金免疫・アレルギー等研究事業 (免疫・アレルギー部門) 研究報告書, p200-202, 1999.
6) Wilder R L, et al:Rheumatoid arthritis:epidemiology, pathology, and pathogenesis. In Primer on Rheumatic Disease. (Schumacher HR Jr, et al eds), p86-89. Arthritis Foundation, Atlanta, 1993.
7) Dugowson C E et al:Rheumatoid arthritis in women:incidence rate in group health cooperative, Seattle, Washington, 1978-1989. Arthritis Rheum 34:1502-1507, 1991.
8) Winchester R:The molecular basis of susceptibdity to rheumatoid arthritis. Adv Immunol 56:389-466, 1994.
9) Weyand C M, et al:The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis Ann Intem Med 117:801-806, 1992.
10) Winchester R, et al:The genetic basis of rheumatoid arthritis:the shared epitope hypothesis. Rheum dis Clin North Am 18:761-783, 1992.
11) Silman A J, et al:Twin concordance rates for rheumatoid arthritis:results from a nation wide study. Br J Rheum 32:903-907, 1993.
12) Pincus T, et al:Early mortality in RA predicted by poor clinical status. Bull Rheum Dis 41:1-4, 1992.
13) 山田昭夫:慢性間接リウマチの死因と生命予後に関係する因子について. 厚生省長期慢性疾患総合研究事業リウマチ調査研究総合研究報告書. p139-141, 1996.

第2章 関節リウマチの病理・病態生理

P.33 掲載の参考文献
1) 澤井高志:関節炎の病理学. リウマチ学, p353-363. 同文書院, 東京, 1989.
2) 澤井高志:リウマチ性疾患の病理. 最新内科学体系免疫・アレルギー性疾患慢性関節リウマチ. (井村裕夫, 他編) p89-107. 中山書店, 東京, 1993.
3) Fox R I et al:Structure and Function of Synoviocyte in Arthritis and allied conditions. (McCarty D J, et al, eds) P263-27& Lea & Febiger, Philaderphia-London, 1993.
4) Scott D L, et al:Significance of fibronectin in rheumatoid arthritis and osteoarthrosis. Ann Rheum Dis 40(2):142-153, 1981.
5) 澤井高志, 他:慢性関節リウマチ滑膜初期病変の免疫組織化学的検討‐モノクローナル抗体を用いた炎症性細胞の定性ならびに定量的解析. リウマチ 30(4):247-254, 1990.
6) Sawai T, et al:In situ hybridization of stromelysin mRNA in the synovial biopsies fromrheumatoid arthritis. Tohoku J Exp Med 178:315-330, 1996.
7) Schumacher H R Jr, et al:Histological appearance of the synovium in early rheumatoid arthritis. Sem Arthritis Rheum 23(6 Suppl 2):3-10, 1994.
8) Klareskog L et al:Immune functions of human synovial cells. Phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum 25 (5):488-501, 1982.
9) Poulter L W, et al:Histochemical discrimination of HLA-DR positive cell populations in the normal and arthritic synovial lining. Clin Exp Immunol 48 (2):381-388, 1982.
10) Stojan B, et al:Chemotactic effect of joint effusions. Ann Rheum Dis 33(5) 425-427, 1974.
11) Takeuchi K, et al:Biochemical investigation of cell motile activity in rheumatoid synovial fluid. J Rheumatol 25(1):9-15, 1998.
12) Maeda S, et al:Determination of interstitial collagenase (MMP-1) in patients With rheumatoid arthritis. Ann Rheum Dis 54(12):970-975, 1995.
13) Yoshihara Y, et al Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59(6):455-461, 2000.
14) 宗像孝佳, 他:慢性関節リウマチにおけるIL-18の動態リウマチ 41(3):625-634, 2000.
17) Zvaifler N J, et al:Pannus and Pannocytes-Alternative models of joint destuction in rheumatoid arthritis. Arthrits Rheum 37(6):783-789, 1994.
18) 井上尚美, 他:慢性関節リウマチ (RA) 関節破壊に関与する酸性プロテアーゼ (cathepsin D) の活性化機構に関する免疫組織化学的解析. 炎症 15(4):505-507, 1995.
19) 田中真希, 他:MRL/Mp-lpr/lpr (MRL/1) マウス関節病変における軟骨, 骨組織の変化 (第1報)-ossification groove of Ranvierの関節破壊の場としての意義‐. 炎症 17(2):129-134, 1997.
23) Yatsugi N, et al:Apoptosis of articular chondrocytes in rheumatoid arthritis and osteoarthritis:correlation of apoptosis with degree of cartilage destruction and expression of apoptosis-related proteins of p53 and c-myc. J Orthop Sci 5(2):150-156, 2000.
24) 長田重一:加熱しているアポトーシス研究実験医 17(13):1598-1602, 1999.
25) Uzuki M, et al:Apoptotic chondrocyte and matrix metalloproteinases in rheumatoid arthiritis. Arthritis Rheum 43 (suppl):1915, 2000.
26) Seki M, et al:Matrix metalloproteinase 9 (MMP-9) in patients with rheumatoid arthritis. Jap J Rheumatol 7(3):197-209, 1997.
27) 伊藤 崇, 他:慢性関節リウマチ血清, 関節液中のMetalloproteinase (MMP-13) の動態-血清, 関節液の濃度, 活性化と関節組織での蛋白, mRNAの発現-. リウマチ 42(1):60-69, 2002.
29) Feldmann M, et al:Anti-TNF alpha therapy of rheumatoid arthritis:what have we learned. Ann Rev Immunol 19:163-196, 2001.
30) Charles P, et al:Regulation of cytokines, cytokine inhibitors, and acute phase proteins of following and anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163(3):1521-1528, 1999.
P.44 掲載の参考文献
2) Arend W P, et al:Cytokine network. In Rheumatoid arthritis:frontiers in pathogenesis and treatment (Firestein G S, et al, eds), p147-163. Oxford University Press, Oxford 2000.
3) Firestein G S, et al:Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 39 (11):1781-1790, 1996.
4) Katsikis P D, et al:Immunoregulatory role of interleukin-10 (IL-10) in rheumatoid arthritis. J Exp Med 179(5):1517-1527, 1994.
6) Paleolog E M:Angiogenesis in rheumatoid arthritis. Arthritis Res 4 (Suppl 3):S81-90, 2002.
7) Park C C, et al:Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167(3):1644-1653, 2001.
9) McInnes I B, et al:The role of interleukin-15 in T-cen migration and activation in rheumatoid arthritis. Nat Med 2(2):175-182, 1996.
11) Olee T, et al:IL-18 is produced by articular chondrocytes and induced proinflammatory and catabolic responses. J Immunol 162(2):1096-1100, 1999.
12) Goldring S R, et al:Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12(3):200-204, 2000.
13) Takayanagi H, et al:Involvement of receptor activator of nuclear factor κB ligand/osteoblast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43(2):259-269, 2000.
14) Kobayashi K, et al:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction J Exp Med 191(2):275-286, 2000.
18) Karin M, et al:Phosphorylation meets ubiquitination:the control of NF-κB activity. Annu Rev Immunol 18:621-663, 2000.
19) Kawanaka N, et al:CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum (in press).
20) Handel M L, et al:Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 md p65. Arthritis Rheum 38(12):1762-1770, 1996.
22) Yamamura M, et al:Interferon-γ-inducing activity of interleukin-18 in the joint of rheumatoid arthritis. Arthritis Rheum 44(2):275-285, 2001.
23) Firestein G S, et al:How important are T cells in chronic rheumatoid synovitis?:II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 46(2):298-308, 2002.
24) McInnes I B, et al:Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 3(2):189-195, 1997.
26) Qin S, et al:The chemokine receptors CX CR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101(4):746-754, 1998.
27) van der Graaff W L, et al:Prognostic value of Th1/Th2 ratio in rheumatoid arthritis. Lancet 351(9132):1931, 1998.
29) Aarvak T, et al:IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162 (3):1246-1251, 1999.
30) Chabaud M, et al:Human interleukin-17:a T cell, derived proinflammatory cytokme produced by the rheumatoid synoium. Arthritis Rheum 42(5):963-970, 1999.
32) Jovanovic D V, et al:IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-a, by human macrophages. J Immunol 160(7):3513-3521, 1998.
33) Chabaud M, et al:Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161(1):409-414, 1998.
P.55 掲載の参考文献
2) 塩沢俊一, 他:慢性関節リウマチと疾患遺伝子. 最新医 56:833-844, 2001.
3) Jawaheer D, et al:A genomewide screen in multiplex rheumatoid arthritisfamilies suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 68:927-936, 2001.
4) 坂口教子, 他:リウマチの新しい動物モデル. Med Pract 15:2065-2068, 1998.
5) Albani S, et al:multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunology Today 17:466-470, 1996.
6) 佐々木毅:ヒトパルボウイルスB19 と慢性関節リウマチ. リウマチ 39:867-873, 1999.

第3章 関節リウマチの関節外病変肺

P.65 掲載の参考文献
1) Fewins H E, et al:High definition computed tomography in rheumatoid arthritis associated pulmonary disease. Br J Rheumatol 30(3):214-216, 1991.
2) Anaya J M, et al:Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 24(4):242-254, 1995.
3) Wolfe F:The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 27(3):630-637, 2000.
4) Cortet B, et al:Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 56:596-600, 1997.
5) Despaux J, et al:Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. Rev Rhum Engl Ed 65 (7-9):453-461, 1998.
8) 河端美則:特発性間質性肺炎1-病理像と亜分類. 治療学 36 (6);561-564, 2002.
9) 大石尚史, 他:慢性関節リウマチの肺病変の病理と臨床像. 臨床リウマチ 11(4):269-274, 1999.
10) Liebow A A, et al:Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 8:1-31, 1975.
11) Katzenstein A L, et al:Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 18(2):136-147, 1994.
12) American Thoracic Society. Idiopathic pulmonary fibrosis:diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) Am J Respir Crit Care Med 161(2 Pt 1):646-664, 2000.
13) 近藤康博, 他:外科的生検肺の組織学的分類に基づく膠原病随伴間質性肺疾患の臨床的特徴と予後. 日呼吸会誌 38(4):259-266, 2000.
15) Dawson J K, et al:Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56(8):622-627, 2001.
16) Rajasekaran B A, et al:Interstitial lung disease in patients with rheumatoid arthritis:a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford) 40 (9):1022-1025, 2001.
18) Dawson J K, et al:Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 61(6):517-521, 2002.
19) Mack U, et al:Fatal diffuse alveolar damage after gold medication. Pneumologie 48(5):405-408, 1994.
20) Zisman D A, et al:Drug-induced pneumonitis:the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 18(3):243-252, 2001.
21) Ogawa D, et al:Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 39 (12):1422-1424, 2000.
22) Salomaa E R, et al:Complement components and their activation products in pleural fluid Chest 114(3):723-730, 1998.
23) Inokuma S, et al:Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. J Rheumatol 23(7):1282-1285, 1996.
P.72 掲載の参考文献
1) Nakano M, et al:Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50(3):154-160, 1998.
2) Helin H J, et al:Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 38(2):242-247, 1995.
3) Saito T, et al:An ultrastructural study of glomerular basement membrane in rheumatoid arthritis patients with urinary abnormalities. Clin Nephrol 43(6):360-367, 1995.
6) Nakano M, et al:Determination of IgA-and IgM-rheumatoid factors in patients With rheumatoid arthritis with and without nephropathy. Ann Rheum Dis 55(8):520-524, 1996.
7) Korpela M et al:Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol 36(11):1189-1195, 1997.
8) Hall C L, et al The natural course of gold nephropathy:long term study of 21 patients. Br Med J 295(6601):745-748, 1987.
9) Hall C L, et al Natural course of penicillamine nephropathy:along term study of 33 patients. Br Med J 296(6629):1083-1086, 1988.
10) 中野正明, 他:臓器病変・診かたの進歩1) 腎障害. 日内会誌 86(10):1351-1357, 1997.
11) 中野正明, 他:腎疾患. リウマチ科 12(4):239-246, 1994.
12) 中野正明:抗リウマチ薬による腎障害. 腎と透析 47(3):365-369, 1999.
13) Mangge H, et al:Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis Clin Chim Acta 300(1-2):195-200, 2000.
14) Nagata M, et al:Glomerular crescents in renal amyloidosis:an epiphenomenon or distinct pathology? Pathology Int 51(3):179-186, 2001.
15) Ito S, et al:Renal stones in patients with rheumatoid arthritis. J Rheumatol 24(11):2123-2128, 1997.
16) 野崎 司, 他:「尿沈渣検査法2000」の概要. 検と技29 (6):518-524, 2001.
17) 中野正明, 他:慢性関節リウマチ(RA)の腎生検組織所見の経年的推移に関する検討. リウマチ 41(2):422, 2001.
P.80 掲載の参考文献
1) 稲田進一:慢性関節リウマチと二次性アミロイドーシス. リウマチ 40(5):849-856, 2000.
3) 豊島 元, 他:剖検輯報からみた慢性関節リウマチの死因-とくにアミロイドーシスとの関連から-. リウマチ 33(3):209-214, 1993.
4) Tiitinen S, et al:Amyloidosis:incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol 22:158-161, 1993.
5) 奥田恭章, 他:アミロイドーシスの診療. リウマチ科 27(suppl 1):933-938,2002.
6) 奥田恭章, 他:アミロイドーシス合併RAの早期診断と予後. リウマチ科 21(5):460-465, 1999.
7) 松田剛正:消化管アミロイドーシス. リウマチ科 21(5):446-450, 1999.
8) Korpela M, et al:Isolated microscopic hematuria in patients with rheumatoid arthritis compared with age and sex matched controls.A population based study. J Rheumatol 22:427-431, 1995.
9) Helin H J, et al:Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 38:242-247, 1995.
10) 中野正明, 他, RAアミロイドーシスの腎障害. リウマチ科 21(5):451-459, 1999.
11) 中村正, 他:慢性および悪性関節リウマチの死因に関する臨床的研究. リウマチ 41(4):736-744, 2001.
12) 奥田恭章, 他:慢性関節リウマチに合併した 2次性アミロイドーシス124 例の臨床的検討-胃-二指腸生検による診断と予後を中心として-. リウマチ 34(6):939-946, 1994.
13) 安田正之:「MTX療法」におけるMTX選択基準に関して. 日本臨床リウマチ学会誌 13 (9):174-181. 2001.
14) 安田正之, 他:慢性関節リウマチ患者におけるメトトレキセートによる骨髄障害.-国内外の報告の総覧-. 医療 55(7):311-321, 2001.
15) 海津嘉蔵, 他:ネフローゼ症候群と抗血小板療法. 日内会誌 86:1639-1643, 1997.
16) Crofford L J:Specific cyclooxygenase-2 inhibitors:what have we learned since they came into widespread clinical use? Curr Opin Rheumatol 13:225-230, 2002.
17) Ylinen K, et al:Outcome of patients with secondary amyloidosis in dialysis treatment Nephrol Dial Transplant 7:908-912, 1992.

第4章 関節リウマチの類縁疾患

P.89 掲載の参考文献
1) Bevans M, et al The systemic lesions of malignant rheumatoid arthritis. Am J Med 16:197-211, 1954.
2) 厚生省特定疾患悪性関節リウマチ・結節性動脈周囲炎研究班 (班長塩川優一):悪性関節リウマチの診断の手引き1973年度研究報告書:4-5, 1974.
3) 橋本博史, 他:悪性関節リウマチの改定診断基準と治療指針 (案) 厚生省特定疾患系統的脈管障害調査研究班1987年度研究報告書, 189-191, 1988.
4) 橋本博史, 他:悪性関節リウマチの改定診断基準の提唱. リウマチ 29:268-276, 1989.
5) 京極方久, 他:悪性関節リウマチの病理組織学的特徴. リウマチ 15:483-487, 1975.
6) Watts R A, et al:The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol 33 (9):832-833, 1994.
7) 橋本博史, 他:悪性関節リウマチ小委員会報告 厚生省特定疾患系統的脈管障害調査研究班1986年度研究報告書, p33. 1987.
8) Puechal X, et al:Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. Aclinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 38 (11):1618-1629, 1995.
9) Voskuyl A E, et al:Factors associated with the development of vasculitis in rheumatoid arthritis:results of a case-control study. Ann Rheum Dis 55(3):190-192, 1996.
10) Callen J P, et al:Granulomatous cutaneous rheumatoid vasculitis. J Rheumatol 15 (6):1005-1008, 1988.
11) Geirsson A J, et al:Clinical and serological features of severe vasculitis in rheumatoid arthritis:prognostic implications. Ann Rheum Dis 46(10):727-733, 1987.
12) 山田昭夫, 他:悪性関節リウマチにおける線溶亢進について. 厚生省特定疾患系統的脈管障害調査研究班1988年度報告書, p34-35. 1989.
13) 中村正, 他:慢性および悪性関節リウマチの死因に関する臨床的研究. リウマチ 41(4):736-744, 2001.
14) Voskuyl A E, et al:The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 39 (11):266-271, 1996.
15) 高林克日己, 他:日和見感染時の悪性関節リウマチに対する短期的プラズマフェレーシス療法. 日臨免疫会誌 10:86-90, 1987.
16) Scott D G, et al:Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76(3):377-384, 1984.
17) 鶴田敬郎, 他:当センターにおける低量Cyclosporine A投与による悪性関節リウマチの治療成績. 九州リウマチ 18:8-12, 1999.
18) Stone J H, et al:Etanercept combined with conventional treatment in Wegener:s granulomatosus:a six-month open-label trial to evaluate safety. Arthritis Rheum 44(5):1149-1154, 2001.
19) 高林克日己, 他:自己免疫疾患患者にみられる日和見感染症の検討. 日内会誌 78:1294-1298, 1989
P.99 掲載の参考文献
1) Harrington J, et al:Developmental issues in adolescence and the impact of rheumatic disease. In:Adolescent Rheumatology (Isenberg D A, et al, eds), p21-34. Martin Dunitz, London, 2000.
2) Fink C W:Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 22:1566-1569, 1995.
3) 横田俊平:小児慢性関節炎の最近の治療法の進歩. リウマチ 39:860-866, 2000.
4) Rooney M, et al:Inflammatory cytokine responses in juvenile chronic arthriti. Br J Rheumatol 34:454-460, 1995.
5) Clutterbuck R et al:Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cell Exp Hematol 28:1120-1128, 2000.
6) Yokota S, et al:Therapeutic efficacy of humanized anti-IL6-receptor antibody in systemic juvenile idiopathic arthritis (abstract). The 2001 65th Annual Scientific Meeting of the American College of Rheumatology.
7) Stephan J L, et al Macrophage activation syndrome and reumatic disease in chidhood:a report of four new cases Clin Exp Rheumatol 11:451-456, 1993.
8) 今川智之, 他:マクロファージ活性化症候群:高サイトカイン血症とその病態. Mol Med 33:1052-1060, 1996.
9) 横田俊平:若年性関節リウマチとぶどう膜炎. リウマチ 34:790-794, 1994.
10) 横田俊平, 他:若年性関節リウマチに対する DMARDs治療法の新展開~メトトレキサートを中心とするMAP療法の試み. 小児科 36:271-281, 1995.
P.108 掲載の参考文献
1) Valtonen J M O, et al:Serological findings in patients with acute syndromes fulfilling the proposed criteria of adult onset Still's disease. Scand J Rheumatol 26:342-345, 1997.
2) Fishman D, et al:The effect of novel polymorphysm in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998.
3) Donn R P, et al:Anovel 5'-franking region polymorphysm of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782-1785, 2001.
4) Normand N J, et al:Lower expression of perforin in CD8+T cells of patients with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 43(Suppl):S406, 2000 (Abstract).
5) Hoshino T, et al:Elevated serum IL-66, IFN-γ and TNF-a levels in patients with adult Still's disease. J Rheumatol 25:396-398, 1998.
6) Wakai K, et al:Estimated prevalence and incidence of adult Still's disease:findings by a nationwide epidemiological survey in Japan. J Epidemiol 7:221-225, 1997.
7) Ohta A, et al:Adult Still's disease:a multi-center survey of Japanese patients. J Rheumatol 17:1058-1063, 1990.
8) Pouchot J, et al:Adult Still's disease:manifestations, disease course, and outcome in 62 patients. Medicine 70:118-136, 1991.
9) Wouters J M G W, et al:Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases. Quart J Med 61:1055-1063, 1986.
10) 山口雅也, 他:成人スチル病にみられる皮疹. 医事新報 3469:37-40, 1990.
11) Stephan J L, et al:Macrophage activation syndrome and rheumatic disease in childhood:a report of four new cases Clin Exp Rheumatol 11:451-456, 1993.
12) Yamaguchi M, et al:Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424-430, 1992.
13) Fujii T, et al:Methotrexate treatment in patients with adult onset Still's disease retrospective study of 13 Japanese cases Ann Rheum Dis 56:144-148, 1997.
14) Marchesoni A, et al:Cyclosporin A in the treatment of adult-onset Still's disease. J Rheumatol 24:1582-1587, 1997.
15) 大田明英, 他:成人Still病の治療と経過-全国調査集計より-. 厚生省特定疾患自己免疫疾患調査研究班平成7年度研究報告書, p.163-165. 1996.
16) Prahalad S, et at Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 28:2120-2124, 2001.

第5章 関節リウマチの診断

P.115 掲載の参考文献
1) Arnett F C, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
2) Lipsky P E:Rheumatoid arthritis. In:Harrison's Principles of Internal Medicine, 15th edition, (Braunwald E, et al, eds), p1928-1937. McGraw-Hill, Columbus, 2001.
4) American College of Rheumatology Subcommittee on Rheumatoid arthritis guidelines:Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 46:328-346, 2002.
5) 近藤啓文, 他:日本リウマチ学会による早期慢性関節リウマチの早期診断. 3. 診断基準の検証. リウマチ 40:54-59, 2000.
7) Scott D L:The diagnosis and prognosis of early arthritis:rationale for new prognostic criteria. Arthritis Rheum 46:286-290, 2002
8) Felson D T, et al:The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729-740, 1993.
9) Pinals R S, et al Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308-3115, 1981.
P.125 掲載の参考文献
1) American college of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines:Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 46:328-346, 2002.
3) Bukhari M, et al:Time to first occurrence of erosions in inflammatory polyarthiritis Results from a prospective community-based study. Arthritis Rheum 44:1248-1253, 2001.
4) O:Dell JR:Treating rheumatoid arthritis early:A window of opportunity. Arthritis Rheum 46:283-285, 2002.
5) Huizinga T WJ, et al:Criteria for early rheumatoid arthritis. From Baye:s how revisited to new thoughts on pathogenesis. Arthritis Rheum 46:1155-1159, 2002.
6) Scott D L:The diagnosis and prognosis of early arthritis:rationale for new prognostic criteria Arthritis Rheum 46:286-290, 2002.
7) Visser H, et al:How to diagnose rheumatoid arthritis early. Arthritis Rheum 46:357-365, 2002.
8) Scottish Intercollegiate Guidelines Network:Management of early rheumatoid arthritis/ Scottish Interconegiate Guidelines Network SIGN Publication No. 48 Edinburgh:Royal College of Physicians:December 2000.
9) Brennan P, et al:Asimple algorithm to predict the development of radiological erosionsin patients with early rheumatoid arthritis:prospective cohort study. B M J 313:471-476, 1996.
10) Van Leeuwen M A, et al:Individual relationship between progression of radiological damage and the acute phase responsein early rheumatoid arthritis:towards development of a decision support system. J Rheumatol 24:20-27, 1997.
11) Bukhari M, et al:Rheumatoid factor is themajor predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Results from the Norfolk Arthritis Register Study, a large Inception Cohort. Arthritis Rheum 46:906-912, 2002.
12) Boers M, et al:Inflammation and damage in an individual joint predict further damage inthat joint in patients with early rheumatoid arthritis. Arthritis Rheum 44:2242-2246, 2001.
13) Papadopoulos I A, et al:Clinical Course andoutcome of early rheumatoid arthritis. Rheumatol Int 20:205-210, 2001.
14) Jansen L M A, et al:Predictors of radiographicjoint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924-927, 2001.
15) Union A, et al:Identification of citrullinated rheumatoid arthritis-specfic epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 46:1185-1195, 2002.
16) Forslind K, et al:Antfilaggrim antibodies inearly rheumatoid arthritis may predict radiological progression. Scand J Rheumatol 30:221-224, 2001.
17) Serre G:Auto antibodies to filaggrin/deiminated fibrin (FA) are usefull for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease. Joint Bone Spine 68:103-105, 2001.
18) Aho K, et al:Antifilaggrin antibodies within "normar" range predict rheumatoid arthritisin a linear fashion. J Rheumatol 27:2743-2746, 2000.
19) Biggaro N, et al:Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoidarthritis. Clinical Chemistry 47:1089-1093, 2001.
21) Cunnane G, et al:Early joint erosions and serum levels of matrix metallo-proteinase 1, metalloproteinase 3, and tissue inhibitor ofmetallo-proteinase 1 in rheumatoid arthritis. Arthritis Rheum 46:2263-2274, 2001.
22) Posthumns M D, et al:Serum matrix metallo-proteinase 3 in early rheumatoid arthritis iscorrelated with disease activity and radiological progression. J Rheumatol 27:2761-2768, 2000.
23) Combe B, et al:Prognistic factors for radiographic damage in early rheumatoid arthritis. A multiparameter prospective study. Arthritis Rheum 44:1736-1743, 2001.
P.135 掲載の参考文献
1) 高岸憲二:滑膜切除の方法. 臨床整形外科手術全書, p.136. 金原出版東京, 1994.
2) 松井宣夫, 他:慢性関節リウマチの画像診断. リウマチ 34:993, 1994.
4) Steinbrocker O T:Therapeutic criteria in rheumatoid arthritis J Amer Med Ass 140:659, 1949.
5) Larsen A, et al:Radiographic evaluation of rheumatoid arthritis and related condition by standard reference films. Acta Radiologica Diagnosis 18:481, 1997.
6) 工藤興亮, 他:三次元画像の基礎と応用. 整形災害外科 40:1227-1233, 1997.
7) Burk D L, et al:Recent advances in magnetic resonance imaging of the knee. Radiol Clin North Am 28:378-393, 1990.
8) Shulte M, et al:Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40:1637-1643, 1999.
P.149 掲載の参考文献
1) Van Riel PLCM, et al:Clinical assessments in rheumatoid arthritis in:Therapy of systemic rheumatic disorders (van de Putte LBA, et al,eds), p31-43. Marcel Dekker, Inc, New York, 1998.
2) Felson D T, et al:The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729-740, 1993.
3) 近藤啓文:慢性関節リウマチの活動性判定(ACRコアセットなど). リウマチ 37:825-831, 1997.
4) Lansbury J:Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis. Arthritis Rheum 1:505-522, 1958.
5) Felson D T, et al:Time for changes in the design, analysis and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 33:140-149, 1990.
6) OMERACT Conference on outcome measures in rheumatoid arthritis clinical trials. J Rheumatol 20:525-591, 1993.
7) Tugwell P, et al:A methodologic framework for developing and selecting endopoints in clinical trials. J Rheumatol 9:758-756, 1982.
8) American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials:Reduced joint counts in rheumatoid arthritis clinical trials. Arthritis Rheum 37:463-464, 1994.
9) Felson D T, et al:American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735, 1995.
10) Roberts R S:Pooled outcome measures in arthritis:the pros and cons. J Rheumatol 20:566-567, 1993.
11) Van der Heijde DMFM, et al:Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 20:538-541, 1993.
12) 鎮痛消炎剤の臨床評価方法に関する研究班:鎮痛消炎剤の臨床評価方法に関するガイドライン. 新薬臨床評価ガイドライン1994 (日本公定書協会編), p507-522. 薬事日報社, 東京, 1994.
13) 井上哲文, 他:日本リウマチ財団薬効検定委員会による抗リウマチ薬・療法の臨床試験実施基準. リウマチ 37:516-520, 1997.

第6章 関節リウマチの管理・治療

P.157 掲載の参考文献
1) 柏崎禎夫, 他:慢性関節リウマチの今日の治療戦略 リウマチ 36(5):713-802, 1996.
2) Wilske K, et al:Remodeling the pyramid:a concept whose time has come. J Rheumatol 16:565-567, 1989.
3) ACR Ad Hoc Committee on clinical guidelines; Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39(5):713, 1996.
4) Felson D T, et al:American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735, 1995.
P.164 掲載の参考文献
1) Vane J R:Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drug. Nat New Biol 231(25):232-235, 1971.
2) Xie W L, et al:Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88(7):2692-2696, 1991.
3) Kujubu D A, et al TISIO, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandlin synthase/cyclooxygenase homologue. J Biol Chem 266(20):12866-12872, 1991.
4) Kojima E et af Coexpression of microsomal prostaglandin E synthase with cyclooxyge nase-2 in human rheumatoid synovial cells. J Rheumatol (in press)
5) Kawai S:Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs:a clinical consideration. Inflamm Res 47(Suppl 2):S102-106, 1998.
6) 川合眞一:非ステロイド抗炎症薬. 今日の治療薬2002 (水島裕, 編), p227-234. 南江堂, 東京, 2002.
7) Lanza F L, et al Etodolac, a new nonsteroidal anti-inflammatory drug gastrointestinal micro-bleeding and endoscopic studies. Clin Rheumatol 8 (Suppl 1):5-15, 1989.
8) Chang D M, et al:Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis Clin Rheumatol 20(2) 104-113, 2001.
9) Silverstein F E, et al:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10):1247-1255, 2000.
10) Bombardier C, et al:Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520-1528, 2000.
11) 川合眞一:妊娠, 出産における薬物療法の注意点. リウマチ科 26(1):35-38, 2001.
14) Yamazaki R, et al:Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells J Pharmacol Exp Ther 302(1):18-25, 2002.
15) Kawai S, et al:Induction of apoptosis by celecoxib, not by other seleceive cyclooxygenase 2 inhibitors in rheurnatoid synovial cells, American College of Rheumatorogy 65th Annual Scientific Meeting, Abstract, 2001.
P.172 掲載の参考文献
1) Wako Urano, et al:Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-190, 2002.
2) Adverse effects of sulphasalazine in rheumatoid arthritis patients are associated with diplotype configuration at N-acetyltransferase 2 gene. J Rheumatol. (in press)
3) Weinblatt M E, et al:Methotrexate in rheumatoid arthritis:effects on disease activity in a multicenter prospective study. J Rheumatol 18:334-338, 1991.
4) Lopez-Mendez A, et al:Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 36:1364-1369, 1993.
5) Ortiz Z, et al:The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36-43, 1998.
6) Menninger H, et al:A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060-1068, 1998.
7) Jesspp J D, et al A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 37:992-1002, 1998.
8) Capell H A, et al:Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. J Rheumatol 25:1880-1886, 1998.
9) The Australian Multicentre Clinical Trial Group:Sulfasalazine in early rheumatoid arthritis. J Rheumatol 19:1672-1677, 1992.
10) Yasuda M, et al:Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate. J Rheumatol 21:44-50, 1994.
11) Nakamura H, et al:Clinical effects of actarit in rheumatoid arthritis:improvement of early disease activity mediated by reduction of serum concentrations of nitric oxide. CUn Exp Rheumatol 18:445-450, 2000.
12) Takei S:Mizoribine in dhe treatment of rheumatoid arthritis and juvenne idiopathic arthritis. Pediatr Int 44:205-209, 2002.
13) Emery P, et al:A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39:655-665, 2000.
14) Smolen J S, et al:Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353 (9149):259-266, 1999.
15) Pincus T, et al:Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis:apreventive strategy. Ann Intern Med 131:768-774, 1999.
17) American College of Rheumatology Subcomittee on rheumatoid arthritis guidelines:Guideline for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 46:328-346, 2002.
18) Plant M J, et al:Relationship between timeintegrated Creactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 43:1473-1477, 2000.
19) Pinals R S, et al Preliminary criteria for clinical remission in rheurnatoid arthritis Arthritis Rheum 24:1308-1315, 1981.
P.182 掲載の参考文献
1) Hench P S, et al:The effect of a hormone of the adrenal cortex (17-hydroxy-11-deoxy-corticosterone;compaound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24:181, 1949.
2) Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of prednisolone with aspirin and other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 19:331-337, 1960.
3) Kirwan J R and the Arthritis and Rheumatism Council Low-dose Glucoconicoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333:142-146, 1995.
4) 鈴木康夫, 他:ステロイドの消炎鎮痛作用と副作用. 痛みと臨 1:224-230, 2001.
5) Pincus T, et al:Are long-term very low dose of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 136:76-78, 2002.
6) 鈴木康夫, 他:慢性関節リウマチ-最近の動向-ステロイド剤. 診断と治療 76:307-310, 1988.
7) Harris E D, et al:Low dose prednisolone therapy in rheumatoid arthritis. A double blind study. J Rheumatol 10:713-721, 1983.
8) Hickling P, et al:and the Arthritis and Rheumatism Council Low-dose Glucocorticoid Study Group:Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis Br J Rheumatol 37:930-936, 1998.
9) van Everdingen A A, et al:Low-dose prednisone therapy for patients with early active rheumatoid arthritis:Clinical Efficacy, disease-modifying properties, and side effects. Ann Intern Med 136:1-12, 2002.
10) Ichikawa Y, et al:ECG abnormalities in steroid-treated rheumatoid arthritis. Lancet 2:828, 1977.
11) van Staa T P, et al:Use of oral corticoster-oids and risk of fractures J Bone Miner Res 15:993-1000, 2000.
12) 鈴木康夫, 他:慢性関節リウマチにおける骨病変. 日臨 60(suppl 3):407-417, 2002.
P.190 掲載の参考文献
1) Jenkins J K, et al:Biological modifier therapy for the treatment of rheumatoid arthritis. Am J Med Sci 323:197-205, 2002.
2) Criscione L G, et al:Tumor necrosis factor-α antagonists for the treatrnent of rheumatic diseases Curr Opin Rheumatol 14:204-211, 2002.
3) Kempeni J:Update on D2E7:a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann Rheum Dis 59(suppl 1):i44-45, 2000.
5) Sigidin Y A, et al:Randomized, double-blind trial of anti-interferon-y antibodies in rheumatoid arthritis. Scand J Rheumatol 30:203-207, 2001.
6) Nishimoto N, et al Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59(Suppl 1):i21-27, 2000.
7) Maini R N, et al:Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor (TNF) α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563, 1998.
8) Lipsky P E, et al:Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602, 2000.
9) Keane J, et al:Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098-1104, 2001.
11) Weinblatt M E, et al:Atrial of etanercept, arecombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259, 1999.
12) Bathon J M, et al:Acomparison of etanercept and methotrexate in patients with earlyrheumatoid arthritis. N Engl J Med 343:1586-1593, 2000.
13) Watt I et al:Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist radiologic assessment. Semin Arthritis Rheum 30 (5 Suppl 2):21-25, 2001.
14) 中原英子, 他:抗IL-6レセプター療法. 内科89:301-305, 2002.
15) 中外製薬社内資料 (MRA治験薬概要書).
16) Guidellines for the management of rheumatoid arthritis. 2002 update. Arthrits Rheum 46:328-346, 2002.
P.197 掲載の参考文献
1) 日本リウマチ友の会: '90リウマチ白書, リウマチ患者の実態報告 (総合編). 流 151:8-13, 1990.
2) WHO:International classification of impairment, disabilities, and handicaps, p 184. World Health Organization, Geneva, 1984.
3) 橋本明:慢性関節リウマチのプールによるリハビリテーションの実際. リウマチ科 10:365-376, 1993.
P.206 掲載の参考文献
1) Adams W, et al:Arthrodesis of the hind foot in rheumatoid arthritis. Ortho Clin N Ame 7:827-840, 1976.
2) Dearborn J T, et al:High replacement of an acetabular component inserted without cement in a revision total hip arthroplasty. Result after a mean of ten years. J Bone Joint Surg 81A:469-480, 1999.
3) Engh G A, et al:Amidvastus muscle splitting approach for total knee arthroplasty. J Arthroplasty 12:322-331, 1997.
4) Fujimori J, et al:Ankle arthrodesis in rheumatoid arthritis using an intrarnedullary nail with fins. Foot Ankle Int 20:48-490, 1999.
5) Hanyu T, et al:Survivorship analysis of total knee arthroplasty with the kinematic prosthesis in patients who have rheumatoid arthritis. J Arthroplasty 12:913-919, 1997.
6) 北爪伸仁, 他:髄内釘ねじ横止め法による足関節固定法について. 骨折 9:33-38,1987.
7) Laskin R S, et al:Total knee replacement With posterior cruciate ligament retention in rheumatoid arthritis. Problems and complications. Clin Orthop 345:24-2&1997.
8) 犀川勲, 他:Fin付き髄内釘を用いた足関節固定術の経験. 整形外科 51:855-859, 2000.
9) Schai P A, et a靴Total knee arthroplasty with posterior cruciate retention in patients with rheumatoid arthritis. Clin Orthop 367:96-106, 1999.
10) 清水一郎, 他:慢性関節リウマチの臼底突出に対して骨移植を併用した人工股関節置換術例の検討. 日人工関節会誌 30:293-294, 2000.
11) 清水一郎, 他:リウマチにおける髄内釘を用いた足関節固定術の成績. 関節の外科 17:1-4, 2001.
12) Stone KH, et al:Amethod of ankle stabilization. Clin Orthop 268:102-106, 1991.
13) 高倉義典:慢性関節リウマチ足の手術的療法. New Mook整外 1:248-256, 1997.
14) 辻本晴俊:慢性関節リウマチに対する関節鏡による膝関節鏡視下洗浄療法の効果. 臨リウマチ 12:53-56, 2000.
15) 上野貢生:RAにおける鏡視下膝関節洗浄術の効果. 日関外誌 20(1):55-58,2001.
16) Waslewski G L, et al:Early, incapacitating instability of posterior cruciate ligament retaining total knee arthropbsty J Arthroplasty 13:763-767, 1998.
P.213 掲載の参考文献
1) Masi A T, et al:Articular patterns in the early course of rheumatoid arthritis. Am J Med 75:16-26, 1983.
2) Yamamoto S, et al:Can DMARDs prevent articular destruction in RA? J Orthopaedic Rheumatology 9:52-56, 1996.
3) Ochi T, et al:Natural course of joint destruction and fluctuation of serum Clq levels in patients with rheumatoid arthritis. Arthritis Rheum 31:37-43, 1998.
4) 山田昭夫, 他:慢性関節リウマチの生命予後に関する因子について. 平成7年度厚生省長期慢性疾患総合研究事業リウマチ調査研究総合研究報告書, p151-153. 国立相模原病院事務局, 神奈川, 1996.
5) Wolfe F W, et al:The mortality of rheumatoid arthritis. Arthritis Rheum 37:481-494, 1994.
6) 鈴木厚, 他:慢性関節リウマチ140例の死因に関する検討. リウマチ 34:601-607, 1994.
7) 居村茂明, 他:慢性関節リウマチ患者の実態と下肢に人工関節置換を受けた患者QOLの経年変化. 平成7年度厚生省長期慢性疾患総合研究事業研究報告書, p147-157. 国立相模原病院事務局, 神奈川, 1996.
8) 大田寛:慢性関節リウマチ患者の死因と寿命. リウマチ病セミナーIII (七川歓次監修), p85-94. 永井書店, 大阪,1992.
9) 橋本明, 他:RA患者のQOL:AIMS 2改訂日本語版調査票を用いた多施設共同調査成績. I. 肢体不自由に関与する諸因子の解析. リウマチ 41:9-24, 2001.
11) 松田剛正:消化管アミロイドーシス. リウマチ科 21:446-450, 1999.
12) 豊島良太:慢性関節リウマチにおける骨粗鬆症. リウマチ 40:728-735, 2000.
13) 東午郎, 他:RA骨粗鬆症の検討. 九州リウマチ 18:58-63, 1999.
14) Hanyu T, et al:Structural mechanisms of bone loss in iliac biopsies:Comparison between rheumatoid arthritis and postrnenopausal osteoporosis. Rheumatol Int 18:193-200, 1999.
15) 宗圓聰:リウマチに伴う骨粗鬆症の臨床像. リウマチ科 28:18-23, 2002.
P.222 掲載の参考文献
1) Hazes J M, et al:The bone and joint decade 2000-2010. Jof Rheumatol 27:1-3, 2000.
2) Medhok R et al:Recent advances Rheumatology. BMJ 321:882-885, 2000.
3) WHO. Global key messages. www.boneandjointdecade.org.
4) Brooks P L, et al:The Bone and Joint Decade:2000-2010. Med J Aust 172:307-308, 2000.
5) 厚生労働省大臣官房統計情報部. 第3表 推計患者の年次推移. 平成11年患者調査. p96-101. 東京, 2001.
6) 厚生省統計情報部:通院者の総傷病数. 平成 10年国民生活基礎調査. 東京, 2000.
7) 厚生省統計情報部:性・年齢階級・症状別にみた有訴者率. 平成10年国民生活基礎調査. 東京, 2000.
8) 厚生労働省大臣官房統計情報部:第11表年齢階級・傷病分類・入院-入院外別一般診療医療費の年次推移. 平成11年国民医療費. p54-69. 東京, 2001.
9) 厚生労働省大臣官房統計情報部:傷病分類別. 平成11年患者調査. p52-54. 東京, 2001.
10) 厚生労働省大臣官房統計情報部:第8表年 齢階級・入院-入院外別一般診療医療費構成割合・一人当たりの一般診療医療費の年次推移. 平成11年国民医療費. p44-49, 東京, 2001.
11) 厚生労働省大臣官房統計情報部:第4表医 科診療件数・診療実日数・実施件数・回数・点数, 診療行為 (大分類) ・傷病 (中分類) ・入院-入院外・一般医療-老人医療別 1総数-総数.平成11年社会医療行為別調査報告. p148.東京, 2001.
12) 財団法人 厚生統計協会:第2編衛生の主要指標第1章人口静態. 2001年国民衛生の動向. p37-39. 廣済堂, 東京, 2001.
13) The Arthritis Foundation of Australia. The prevalence, cost and disease burden of arthritis in Australia. Canberra, pl-27, 2001.
14) Doran M E et al:Trends in incidence and Mortality in Rheumatoid Anhritis in Rochester, Minnesota over a forty-year period. Arthritis Rheum 46:625-631, 2002.
15) Symmons D, et al:The prevalence of rheumatoid arthritis in the United Kingdom:new estkmates for a new century. Rheumatology 41:793-800, 2002.
16) Murray C J L et al:Global mortality, disability, and the connibution of risk factors:Global Burden of Disease Study. The Lancet 349:1436-1442, 1997.
17) Brooks P L:Managing arthritis in the Bone and Joint Decade. Med J Aust 175:S91. 2001.

第7章 関節リウマチ治療ガイドライン

P.230 掲載の参考文献
1) Guidelines for the management of rheumatoid arthritis 2002 Update. Arthritis Rheum 46 (2):328-346, 2002.
2) Yamamoto S, et al:Study on Japan Rheumatism Association diagnostic criteria for early rheumatoid arthritis. 1. Application of the American Rheumatism Association diagnostic criteria to Japanese patients with early rheumatoid arthritis. Ryumachi 33(4):354-362, 1993.
3) Singh G:Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105:31S-38S, 1998.
4) van Everdingen A A, et al:Low-dose prednisone therapy for patients with early active rheumatoid arthritis:clinical efficacy, disease-modifying properties, and side effects:a randomized, double-blind, placebo-controlled clinical trial Ann Intern Med 136(1):1-12, 2002.
5) Wilske K R, et al:Remodeling the pyramid-a concept whose time has come. J Rheumatol 16(5):565-567, 1989.
6) Fries J F Reevaluating the therapeutic approach to rheumatoid arthritis the"sawtooth"strategy. J Rheumatol(Suppl) 22:12-15, 1990.
7) Breedveld F C:Is there a place for leflunomide in the treatment of rheumatoid arthritis? Lancet 358(9289):1198-1200, 2001.
8) Moreland L W:Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol(Suppl) 57:7-15, 1999.

最近チェックした商品履歴

Loading...